Interdisciplinary Bio Central
Tutorial (Pharmaceutical bioscience and technology)

Tutorial on Drug Development for Central Nervous System
Hyejin Yoon1 and Jungsu Kim1,*
1Department of Neurology, Washington University Medical School, St. Louis, MO 63110, USA
*Corresponding author
  Received : October 05, 2010
  Accepted : October 07, 2010
  Published : October 11, 2010
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Main text PDF(1568KB)
   (Print version)

Many neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are devastating disorders that affect millions of people worldwide. However, the number of therapeutic options remains severely limited with only symptomatic management therapies available. With the better understanding of the pathogenesis of neurodegenerative diseases, discovery efforts for disease-modifying drugs have increased dramatically in recent years. However, the process of translating basic science discovery into novel therapies is still lagging behind for various reasons. The task of finding new effective drugs targeting central nervous system (CNS) has unique challenges due to blood-brain barrier (BBB). Furthermore, the relatively slow progress of neurodegenerative disorders create another level of difficulty, as clinical trials must be carried out for an extended period of time. This review is intended to provide molecular and cell biologists with working knowledge and resources on CNS drug discovery and development.

Keyword: drug development, blood-brain barrier, drug toxicity, drug safety, drug screening, neurodegenerative diseases,
IBC   ISSN : 2005-8543   Contact IBC